PATENT CLAIM ANALYSIS

Application Number: 15914189
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["514", "265100"]

Abstract:
The invention relates to glucuronide prodrug compounds of the Janus kinase (JAK) inhibitor tofacitinib having formula I: where A 1  and R 1  are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.

Claim (Index 15):
The compound of  claim 14 , wherein the aryl group is unsubstituted.

Metadata:
- Claim Count in Document: 73.0
- Percentile: 90.0
- Lexical Diversity: 1.35556
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15358462', '12503384', '13379301', '15799771', '14082786']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.797021633073412
- 35 USC 102 Novelty (BERT): 0.5409432746725193
- Combined Prediction Score: 0.7714137972333228
- Mean Citation Score: 336.024834
- Max Citation Score: 403.78525
- Similarity Product: 220.5982286638469

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test